1. Sprue-like enteropathy linked to olmesartan.
- Author
-
Campos Ruiz A, Urtasun Arlegui L, and Marra-López Valenciano C
- Subjects
- Aged, Angiotensin II Type 1 Receptor Blockers therapeutic use, Celiac Disease diagnostic imaging, Humans, Hypertension complications, Hypertension drug therapy, Imidazoles therapeutic use, Male, Middle Aged, Tetrazoles therapeutic use, Angiotensin II Type 1 Receptor Blockers adverse effects, Celiac Disease chemically induced, Imidazoles adverse effects, Tetrazoles adverse effects
- Abstract
Olmesartan is a therapy used for the management of hypertension available since 2002. A sprue like enteropathy associated with olmesartan has been first described in 2012. Endoscopic and histopathological findings are partial or total villous atrophy, mimicking a Celiac Disease. We explain two cases diagnosed in our hospital. Both patients took more than one year of treatment with olmesartan. In both cases, the biopsy showed duodenal villous atrophy, negative serology for celiac disease and they improved after stopping treatment with olmesartan. Olmesartan associate sprue-like enteropathy should be included in the differential diagnosis of seronegative villous atrophy. After the discontinuation of olmesartan, clinical remission usually occurs in every patients.
- Published
- 2016
- Full Text
- View/download PDF